- Home
- VERA vs NVCR Comparison
VERA vs NVCR Comparison
Compare VERA & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERA
- NVCR
- Stock Information
- Founded
- VERA 2016
- NVCR 2000
- Country
- VERA United States
- NVCR Switzerland
- Employees
- VERA N/A
- NVCR N/A
- Industry
- VERA Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- VERA Health Care
- NVCR Health Care
- Exchange
- VERA Nasdaq
- NVCR Nasdaq
- Market Cap
- VERA 2.0B
- NVCR 1.9B
- IPO Year
- VERA 2021
- NVCR 2015
- Fundamental
- Price
- VERA $24.00
- NVCR $17.71
- Analyst Decision
- VERA Buy
- NVCR Buy
- Analyst Count
- VERA 8
- NVCR 6
- Target Price
- VERA $64.63
- NVCR $32.83
- AVG Volume (30 Days)
- VERA 2.3M
- NVCR 1.6M
- Earning Date
- VERA 08-07-2025
- NVCR 07-24-2025
- Dividend Yield
- VERA N/A
- NVCR N/A
- EPS Growth
- VERA N/A
- NVCR N/A
- EPS
- VERA N/A
- NVCR N/A
- Revenue
- VERA N/A
- NVCR $621,711,000.00
- Revenue This Year
- VERA N/A
- NVCR $5.56
- Revenue Next Year
- VERA N/A
- NVCR $9.19
- P/E Ratio
- VERA N/A
- NVCR N/A
- Revenue Growth
- VERA N/A
- NVCR 18.27
- 52 Week Low
- VERA $18.53
- NVCR $14.17
- 52 Week High
- VERA $51.61
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- VERA 54.33
- NVCR 51.32
- Support Level
- VERA $22.76
- NVCR $17.53
- Resistance Level
- VERA $23.97
- NVCR $18.70
- Average True Range (ATR)
- VERA 1.21
- NVCR 0.72
- MACD
- VERA 0.15
- NVCR 0.09
- Stochastic Oscillator
- VERA 73.63
- NVCR 60.56
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.